Results of M118 EMINENCE clinical trial published in Circulation

Apr 8 2010

Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that the results of the M118 EMINENCE clinical trial have published in Circulation. The paper, entitled Evaluation of a New Heparin Agent in Percutaneous Coronary Intervention: Results of the Phase 2 Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE) Trial published in the April 5, 2010 "Publish Ahead of Print" online edition of the peer-reviewed journal Circulation: Journal of the American Heart Association (http://circ.ahajournals.org).  Circulation is a preeminent publication with a readership of approximately 23,900 cardiologists, cardiovascular surgeons, electrophysiologists, internists, nurses and others interested in cardiovascular medicine. The Impact Factor of Circulation ranks first among journals in the cardiac & cardiovascular systems, hematology and peripheral vascular disease categories according to Journal Citation Reports® 2009, published by Thomson Scientific.

The key conclusion in the paper is that in this study M118 was well-tolerated and provided further evidence of feasibility for use as an anticoagulant in patients undergoing elective percutaneous coronary intervention. The authors further conclude the data provides the basis for further investigations of M118 in ischemic heart disease.   The first author was Sunil V. Rao, M.D., co-principal investigator for the EMINENCE trial. Dr. Rao is an Assistant Professor of Medicine at the Duke University Medical Center and Director of the Cardiac Catheterization Laboratories at the Durham, NC Veterans Affairs Medical Center.